The website Perficient covered innovations in clinical trial enrollment through technology, and highlighted Antidote's Match. The article explains:
"Last week, Antidote announced it raised $11M in a new funding round that is led by Merck Global Health Innovation Fund (GHI), reinforcing the importance and desire to find more accurate and effective methods of subject recruiting.
To see Antidote Match in action, you can look at how JDRF, the leading global organization funding type 1 diabetes (T1D) research, is leveraging the platform."
Read more at Perficient.
